Table 5.

Exploration of the abscopal effect: best brain response for the overall brain

	All patients (n=15)	Group 1 ICI alone (n=10)	Group 3' ICI plus SRT: patients with more BM than SRT targets (n=5)
Local assessment (n, %)
PD	3 (20)	1 (10)	2 (40)
SD	3 (20)	2 (20)	1 (20)
PR/CR	0	0	0
Data incomplete	9 (60)	7 (70)	2 (40)
	(9 PD prior to 3 months)	(7 PD prior to 3 months)	(2 PD prior to 3 months)
RECIST V.1.1 (MRI only)
PD	5 (23)	2 (20)	3 (60)
SD	0	0	0
PR	0	0	0
CR	0	0	0
Data incomplete	10 (67)	8 (80)	2 (40)
	(9 PD prior to 3 months)	(7 PD prior to 3 months)	(2 PD prior to 3 months)
RANO (MRI, clinical, steroids)
PD	5 (23)	2 (20)	3 (60)
SD	0	0	0
PR	0	0	0
CR	0	0	0
Data incomplete	10 (67)	8 (80)	2 (40)
	(9 PD prior to 3 months)	(7 PD prior to 3 months)	(2 PD prior to 3 months)
iRANO (considering MRI only)
PD	3 (20)	2 (20)	1 (20)
SD	2 (13)	0	2 (40)
PR	0	0	0
CR	0	0	0
Data incomplete	10 (67)	8 (80)	2 (40)
	(9 PD prior to 3 months)	(7 PD prior to 3 months)	(2 PD prior to 3 months)
iRANO (MRI, clinical, steroids)
PD	3 (20)	2 (20)	1 (20)
SD	2 (13)	0	2 (40)
PR	0	0	0
CR	0	0	0
Data incomplete	10 (67)	8 (80)	2 (40)
	(9 PD prior to 3 months)	(7 PD prior to 3 months)	(2 PD prior to 3 months)

BM, brain metastasis; CR, complete response; ICI, immune checkpoint inhibition; iRANO, immunotherapy response assessment in neuro-oncology; n, number of patients; PD, progressive disease; PR, partial response; RANO, response assessment in neuro-oncology; RECIST, response evaluation criteria in solid tumours; SD, stable disease; SRT, stereotactic radiotherapy.